Zynerba Pharmaceuticals — Investor Presentation (December 2018)
30 slides from Zynerba Pharmaceuticals's investor presentation, Dec 17, 2018
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: A Rare/Near-Rare Neuropsychiatric Company
Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 Development efforts focused in rare and near rare neuropsych disorders Deep pipeline focused on high unmet medical needs; translating into multi-billion dollar market opportunity Four clinical shots on goal: FXS, DEE, ASD, 22q Opportunities for efficient deve
Slide 3: Strong Clinical Pipeline
Strong Clinical Pipeline 4 *Orphan Drug Designation Ongoing Planned 2019 Milestones Top line CONNECT-FX data: 2H2019 Additional long term data from FAB-C: 2019 Initiate Phase 2 open label study: 1H2019 Initiate Phase 2 open label study: 1H2019 Top line BELIEVE 1 data: 3Q2019 Assess other neuropsychi
Slide 4: ZYN002 Cannabidiol (CBD) Gel
Neuropsych Indications Differentiated Formulation delivers CBD through the epidermis and into the circulatory system ZYN002 Cannabidiol (CBD) Gel 5 Unique MOA First & only patent-protected, permeation-enhanced, pharmaceutically- produced CBD gel Transdermal CBD binds multiple receptors and mediates
Slide 5: ZYN002 Cannabidiol (CBD) Gel
ZYN002 Cannabidiol (CBD) Gel Differentiated Transdermal Unique MOA Neuropsych Indications CED First & only patent- Formulation CBD binds multiple Potential utility in rare / protected, permeation- delivers CBD receptors and near-rare enhanced, through the mediates numerous neuropsychiatric pharmaceu
Slide 6: Fragile X Syndrome (FXS) Overview
Fragile X Syndrome (FXS) Overview 7 Rare genetic developmental disability Leading known cause of both inherited intellectual disability and autism spectrum disorder Symptoms linked to deficiencies in the endocannabinoid (EC) system ECs form system of neurotransmitters regulating emotional responses,
Slide 7: Fragile X Clinical Program
Fragile X Clinical Program 8 Recent ZYN002 Development Progress Presented 12-month FAB-C open label Phase 2 data at American College of Neuropsychopharmacology meeting (ACNP; Dec. 2018) Statistical improvement from baseline in FXS phenotypic behaviors including social avoidance, anxiety, and irritab
Slide 8: FAB-C Open Label Phase: Month Three Results
FAB-C Open Label Phase 2 10 Baseline: 18.2 Baseline: 14.5 Baseline: 8.7 Baseline: 5.1 Baseline: 7.9 Baseline: 6.1 41.8% 52.9% 54.9% 32.4% 59.5% 42.6% P=0.0005 P=0.0096 P=0.0034 P=0.0018 P=0.0006 P=0.0237 Mean % Improvement from Baseline Month Three: ABC-CFXS Mean Score Percent Improvement in Behavio
Slide 9: FAB-C ABC-CFXS Subscales vs. 3rd Party Data
FAB-C ABC-CFXS Subscales 11 Month Three: Percent Improvement vs. 3rd Party Data* Socially Unresponsive / Lethargic Does not pay attention Inappropriate Speech Repeats words / phrases Stereotypy Repetitive movements Hyperactivity Disrupts group activities Social Avoidance Seeks isolation Irritability
Slide 10: FAB-C Open Label Phase: Month 12 Results
FAB-C Open Label Phase 2 12 Month 12: ABC-CFXS Mean Score 57.9* 51.1* 65.7* 36.7* 60.8* 56.5* *P < 0.05 Percent Improvement in Behavioral Symptoms of FXS Mean % Improvement from Baseline 77.2* 59.2* 72.2* 40.4* 64.9* 56.5* Data from American College of Neuropsychopharmacology (ACNP) meeting, Decembe
Slide 11: FAB-C Safety Summary Through 12 Months
FAB-C Open Label Phase 2 13 Well tolerated, consistent with previously reported data; no SAEs No clinically meaningful trends in vital signs, ECG, or clinical safety labs including LFTs; no THC detected in plasma Discontinuations Two siblings discontinued in Period 1 One for worsening of pre-existin
Slide 12: CONNECT-FX: A Pivotal Trial In FXS
CONNECT-FX: A Pivotal Trial In FXS 14 Clinical study Of CaNNabidiol (CBD) in ChildrEn and AdolesCenTs with Fragile X (CONNECT-FX) ZYN002 250 mg daily 500 mg daily (weight-based dose) Placebo Mirrors ZYN002 administration Patients randomized (1:1) to receive either ZYN002 or placebo Treatment Target:
Slide 13: CONNECT-FX Endpoints
CONNECT-FX: A Pivotal Trial In FXS 15 Primary endpoint: Change from baseline to end of treatment in ABC-CFXS Social Avoidance subscale Key secondary endpoints: Change from baseline to end of the treatment in ABC-CFXS Irritability subscale score ABC-CFXS Socially Unresponsive/Lethargic subscale score
Slide 14: CONNECT-FX Regulatory Plans
CONNECT-FX 16 With positive results, Zynerba intends to request a meeting with the FDA to: Determine acceptability of data as basis for NDA filing Seek advice on marketing authorization preparation Zynerba believes indication may include the treatment of behavioral symptoms associated with FXS Evalu
Slide 15: DEE: Developmental and Epileptic Encephalopathies
DEE Developmental and Epileptic Encephalopathies 17
Slide 16: DEE Overview
DEE Overview 18 Doose Syndrome Dravet Syndrome Early Myoclonic Encephalopathy Juvenile Myoclonic Epilepsy (JME) Landau-Kleffner Syndrome Lennox-Gastaut Syndrome (LGS) Ohtahara Syndrome West Syndrome / Infantile Spasms Heterogeneous group of rare / ultra rare epilepsy syndromes Severe cognitive impai
Slide 17: Developing ZYN002 in DEE
Developing ZYN002 in DEE 19 Enrollment Complete in BELIEVE 1 Trial Compelling rationale for utility of CBD in DEE Third party clinical data show impact of CBD on seizures and behavioral issues in children Patient enrollment in BELIEVE 1 Phase 2 study complete Six month multi-dose study in DEE patien
Slide 18: BELIEVE Phase 2 Trial in DEE
BELIEVE 1 Phase 2 Trial in DEE 20 Open LaBel Study to Assess the Safety and Efficacy of ZYN002 Administered as a TransdermaL Gel to ChIldren and AdolEscents with DeVelopmental and Epileptic Encephalopathy Target: 48 patients Three through 17 years of age Screening Maintenance Titration Open label ex
Slide 19: Autism Spectrum Disorder (ASD) in pediatric patients
21 Autism Spectrum Disorder (ASD) in pediatric patients
Slide 20: ASD in Pediatrics Overview
ASD in Pediatrics Overview 22 Near-rare disorder affecting <1MM pediatric and adolescent pts DSM-5 diagnosis including Autistic, Asperger’s, Rhett’s disorders Symptoms include Anxiety Restricted, repetitive patterns of behavior Impairments in social communication Deficits in verbal and non-verbal co
Slide 21: Developing ZYN002 in ASD
Developing ZYN002 in ASD 23 Newer studies suggest ASD is linked to disruption in the endocannabinoid system Clinical and anecdotal data show improvement in social avoidance and anxiety in children with CBD Exogenous CBD may modulate the endocannabinoid system and improve certain autism-related behav
Slide 22: 22q11.2 Deletion Syndrome (22q)
22q11.2 Deletion Syndrome (22q) 24
Slide 23: 22q Overview
22q Overview 25 Most common contiguous gene deletion syndrome Rare disorder: ~81K patients in US Likely underdiagnosed Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy Neuropsychiatric illnesses (anxiety disorders, ASD) and learning
Slide 24: 22q Patient Management
22q Patient Management 26 Two primary stages of 22q patient management: During infancy, doctors address acute physical concerns, such as anomalies of heart and palate, with surgery Once the physical concerns are stabilized, focus shifts to managing neuropsychiatric symptoms, such as anxiety and auti
Slide 25: Developing ZYN002 in 22q
Developing ZYN002 in 22q 27 CBD may treat neuropsychiatric symptoms in 22q due to activity as: Agonist at serotonin 1A receptors Antagonist at GRP55 receptors Modulator of endocannabinoid system Anxiety may predict adaptive functioning, and is thought to heighten the risk of later development of psy
Slide 26: ZYN002 in Adult Refractory Focal Epilepsy
ZYN002 in Adult Refractory Focal Epilepsy 28 Delaying until after readout of four childhood neuropsych studies Provides additional time to better understand ZYN002 responders Data at 2018 American Epilepsy Society meeting demonstrated strong, sustained response in patients (n=63) in STAR 2 for 18 mo
Slide 27: Financial Strength
Financial Strength 29 Cash and cash equivalent position of $66.2 million as of September 30, 2018 Expected to be sufficient to fund operations and capital requirements into 2H2020
Slide 28: Expected Milestones into 2020
Expected Milestones into 2020 30 1Q 2Q 3Q 4Q FXS FDA meeting DEE Initiate Phase 2 open label study Adult refractory focal epilepsy Present add’l STAR 2 extension data Other indications Initiate Pivotal trial Present add’l Phase 2 FAB-C data 1Q 2Q 3Q 4Q 2018 2019 Present/publish additional data from
Slide 29: Expected Milestones into 2020
Expected Milestones into 2020 2018 2019 | 2020 ca 20 20 a} 1a |! 13a ‘aa ||[ 1a |i{ 20 |
Slide 30: Zynerba Pharmaceuticals
> Zynerba PHARMACEUTICALS Advancing Science | Improving Connections
Zynerba Pharmaceuticals — Investor Presentation (December 2018) on 6ix